There are currently 434 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT06291324
Recruiting
The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Pancreatic Cancer, Breast Cancer
Register for Updates
Exercise to ReGain Stamina and Energy (The EXERGISE Study)
NCT05684367
Recruiting
About 20%-70% of breast cancer survivors experience fatigue after cancer therapy. Because epidemiologic evidence shows that old age is a risk factor for fatigue in adults with cancer history, older breast cancer survivors suffer from even more fatigue than younger survivors. The purpose of this study is to test types of walking exercise interventions and their ability to reduce fatigue in older breast cancer survivors.
Gender:
FEMALE
Ages:
Between 60 years and 105 years
Trial Updated:
01/17/2025
Locations: Institute on Aging; University of Florida, Gainesville, Florida
Conditions: Fatigue, Breast Cancer, Cancer, Therapy-Related
Register for Updates
CDK and Body Composition Study
NCT03697577
Recruiting
The goal of this study is to evaluate changes in body composition among patients who are treated with cyclin-dependent kinase (CDK) 4/6 inhibitors (abemaciclib, ribociclib, or palbociclib).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Breast Cancer
Register for Updates
Oral Aromatase Inhibitors Modify the Gut Microbiome
NCT05030038
Recruiting
The purpose of this research is to study the bacteria in participants' gut before receiving a medicine called an aromatase inhibitor for breast cancer and after participants receive medicine for breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina
Conditions: Breast Cancer
Register for Updates
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT04573231
Recruiting
The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determine its role in resistance to the anti-androgen, bicalutamide. The investigators hypothesize that PSMA expression will correlate with resistance to anti-androgen therapies, as has been documented in prostate cancer, and this can be used to select patients most li... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Conditions: Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Register for Updates
Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function
NCT06081127
Recruiting
The goal of this research study is to determine the feasibility and potential effects of physical therapy and enhanced patient education delivered before breast cancer treatment. Physical therapy before cancer treatment aims to help with early identification and self-management of physical and functional side effects from cancer treatment. Side effects could be joint pain, muscle weakness, or fatigue that contribute to functional impairment. The main questions this study aims to answer are: 1.... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
Rutgers University Study of the Genetics of Breast Cancer.
NCT06773897
Recruiting
The goal of this observational study is to learn more about how genes impact the risk of breast cancer. Anyone 18 or older living in the US is eligible, and a diagnosis of cancer is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Rutgers University, Piscataway, New Jersey
Conditions: Breast Cancer Risk, Breast Cancer Prevention, Breast Cancer
Register for Updates
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: University of Colorado, Aurora, Colorado +5 locations
Conditions: Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Register for Updates
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
ALL
Ages:
All
Trial Updated:
01/10/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona +14 locations
Conditions: Breast Cancer
Register for Updates
Sexual Health in Breast Cancer Patients
NCT05138510
Recruiting
In the present study, we propose a mixed methods approach to characterize and address the sexual health needs among women with breast cancer at the time of diagnosis and throughout treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Breast Cancer
Register for Updates
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT05035836
Recruiting
This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined by pathologic complete response (pCR) .
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, HER2-positive
Register for Updates
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients with Breast Cancer with Nodal Metastases
NCT06092892
Recruiting
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
01/07/2025
Locations: Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California +2 locations
Conditions: Breast Cancer, Axillary Nodal Disease, Female Breast Cancer, Axilla; Breast, Mastectomy; Lymphedema, Tumor, Breast
Register for Updates